Ralfinamide

03/15/2018 - "It is unclear whether ralfinamide is effective against neuropathic pain induced by specified etiologies. "
08/01/2021 - "Ralfinamide has shown anti-nociceptive activity in animal models of inflammatory and neuropathic pain and is currently under phase III clinical trial for neuropathic pain. "
11/01/2007 - "The action of ralfinamide to selectively inhibit tonic firing in nociceptive neurons very likely contributes to the effectiveness of the drug in reducing inflammatory and neuropathic pain as well as bladder overactivity."
03/15/2018 - "Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain."
10/15/2008 - "Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat."

03/15/2018 - "Ralfinamide did not affect physiological pain, locomotion, or cardiovascular function. "
10/15/2008 - "In this study ralfinamide was administered to rats at doses producing plasma levels similar to those causing analgesia in pain patients. "
03/15/2018 - "The effects of ralfinamide on physiological pain were evaluated in mechanical withdrawal, hot plate, and acetic acid writhing tests. "
01/01/2010 - "Ralfinamide is an α-aminoamide derivative with ion channel blocking properties, acting both peripherally and centrally through different molecular targets important in pain control. "
11/01/2007 - "Recent studies revealed that ralfinamide, a Na(+) channel blocker, suppressed tetrodotoxin-resistant Na(+) currents in dorsal root ganglion (DRG) neurons and reduced pain reactions in animal models of inflammatory and neuropathic pain. "

03/15/2018 - "The sodium channel blocker ralfinamide has exhibited potent analgesic effects in several preclinical pain models and in patients with mixed neuropathic pain syndromes (Phase II trials), but it failed to ameliorate neuropathic low back pain in Phase III trials. "

05/01/2013 - "Ralfinamide, an original Na(+) channel blocker developed for the treatment of chronic pain, inhibits monoamineoxidase-B with no apparent effect on monoamineoxidase-A. "
10/15/2008 - "Ralfinamide is analgesic when applied as a single dose in rodent models of stimulus-evoked chronic pain. "

03/15/2018 - "Oral ralfinamide dose-dependently alleviated spared nerve injury-induced allodynia in rats and mice. "
03/15/2018 - "Together, ralfinamide attenuated mechanical allodynia in all the neuropathic pain models tested, with subtle differences in efficacy. "